undamentalytics Newsletter
Sign in

Xencor Inc revenue

Xencor Inc's revenue was $126m in fiscal 2025, up 13.7% on the year before. Since fiscal 2016 ($109m) it has grown at a compound 1.6% a year. Over the last twelve months it was $105m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1094641157123275165175110126105
Growth on the year before—−57.7%−12.0%+285.9%−21.7%+124.2%−40.2%+6.1%−36.7%+13.7%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Royalty $80.3M 63.9% ▲ 18.9%
Milestone $45.3M 36.1% ▲ 31.3%
Licenses $0 0.0% ▼ 100.0%
Collaboration $0 0.0% —

From Xencor Inc's 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Xencor Inc $105m -28.6% -2.5%
Kymera Therapeutics, Inc. $102m 133.8% 29.7%
Septerna, Inc. $98.9m 13520.1% —
Agios Pharmaceuticals, Inc. $98.3m 140.6% 69.6%
ARS Pharmaceuticals, Inc. $117m 4.1% 711.3%
Arcus Biosciences, Inc. $117m -55.3% -1.1%

Compare with peers

Head to head: KYMR vs XNCRSEPN vs XNCRAGIO vs XNCRSPRY vs XNCR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Xencor Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Xencor Inc.